Compare DexCom, Inc. (DXCM) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Sezzle Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Sezzle Inc trades at $128.64 (market cap $3.95B). The key difference: DexCom, Inc. is far larger — about 8.1× Sezzle Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Sezzle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Sezzle Inc for 15 Days on average.
| DXCM | SEZL | |
|---|---|---|
Market Cap | $31.86B | $3.95B |
Volume | 3,607,070 | 550,075 |
Sector | Health | Financials |
52-Week High | $92.34 | $188.55 |
52-Week Low | $54.84 | $50.97 |
Typical Hold Time | 62 Days | 15 Days |
Enterprise Value | $31.32B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
SEZL trades at $117.22, up 2.96% today, showing strong momentum with bullish technical indicators and trading above key support levels. The company demonstrates exceptional financial performance with 51.7% revenue growth in Q2 2026, 30.35% net income margin, and 88.85% ROE. Recent product launches including Sezzle Send and SezzleCash are driving user acquisition and platform growth.
SEZL presents a compelling growth opportunity with analyst consensus price target of $168 representing 43% upside potential. Key risks include competitive BNPL market pressures and potential credit quality concerns. The stock's premium valuation (P/E 25.71) is supported by strong earnings growth and profitability metrics, though investors should monitor execution of expansion initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
